Germline findings in patients with advanced malignancies screened with paired blood–tumour testing for personalised treatment approaches
- 8 November 2022
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 179, 48-55
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The Ensembl Variant Effect PredictorGenome Biology, 2016
- SeqPurge: highly-sensitive adapter trimming for paired-end NGS dataBMC Bioinformatics, 2016
- Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNAJAMA Oncology, 2016
- Germline Mutations in Predisposition Genes in Pediatric CancerNew England Journal of Medicine, 2015
- Prevalence of deleterious ATM germline mutations in gastric cancer patientsOncotarget, 2015
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialThe Lancet Oncology, 2015
- Personalized genomic analyses for cancer mutation discovery and interpretationScience Translational Medicine, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessmentGenetics in Medicine, 2015
- ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencingGenetics in Medicine, 2013